Modality.AI

San Francisco, CAFounded 201811–50 employeesmodality.ai

Modality.AI develops a science-first multimodal assessment platform for evaluating and monitoring neurological and psychiatric conditions in clinical research and care. Its AI-powered virtual guide, Tina, conducts structured conversations that the platform analyzes for audio and visual measures, including speech and facial expression.

Visit modality.ai ↗

Founded: 2018
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

On July 9, 2026, Modality.AI and Amprion announced work combining digital neurology assessments with biomarker research for neurodegenerative disease. The announcement points to a collaboration connecting the company’s multimodal assessment capabilities with biomarker work; it is the clearest recent development in the profile. Earlier, on November 29, 2023, Verge Genomics announced that it would use Modality.AI in an ALS Phase 1b clinical trial of its lead candidate, VRG50635. These collaborations illustrate applications in both biomarker research and clinical-trial assessment. The company’s funding history includes a $570,523 seed round announced October 7, 2024, following a $1,119,113 seed round in October 2022 and a $2,927,860 grant in May 2022. Its listed products include Tina Virtual Agent, which guides structured patient conversations, and Patient Report of Problems™ (PROP™), a natural-language tool for analyzing patients’ own descriptions of symptoms. No specific product launch, award, or leadership change is identified in the available profile.

Market position

Modality.AI operates at the intersection of digital health, neurological assessment, clinical research, and conversational AI. Its stated approach combines structured dialogue with analysis of speech, facial expression, and other audio and visual behaviors, aiming to support remote or in-clinic assessment and monitoring. Tina Virtual Agent conducts patient conversations, while Patient Report of Problems™ (PROP™) analyzes patients’ verbatim descriptions of symptoms. The company’s 2023 use in Verge Genomics’ ALS Phase 1b trial and its 2026 collaboration with Amprion provide concrete examples of clinical research and biomarker applications. The listed industry categories include AI, healthcare, machine learning, natural language processing, software, and video. Its competitive position is therefore best described by its modality mix and research-oriented use cases rather than by a verified ranking against named vendors.

Growth & opportunities

Modality.AI’s development has progressed through a series of seed, grant, and non-equity assistance events rather than a clearly documented large institutional financing. The earliest listed support is non-equity assistance dated January 1, 2021, followed by a $750,700 pre-seed round in April 2021 and a $1,739,953 seed round in July 2021. A $2,927,860 grant in May 2022 and a $1,119,113 seed round in October 2022 mark additional financing milestones. Health Engine provided non-equity assistance in November 2023, and the latest listed financing is a $570,523 seed round dated October 7, 2024. Product development centers on a multimodal neurological and psychiatric assessment platform, Tina Virtual Agent, and PROP™. External clinical milestones include use in Verge Genomics’ ALS Phase 1b trial in November 2023 and the Amprion biomarker collaboration announced in July 2026. These events suggest a trajectory from platform development toward research collaborations and clinical applications. However, the available profile provides no quantified employee growth, hiring activity, revenue, or launch dates, limiting conclusions about the pace of commercialization.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Modality.AI distinct

reccy insights

What makes Modality.AI distinct

01Combines audio and visual analysis of patient conversations to support objective assessments.
02Designed for remote or clinical-setting assessment and monitoring across conditions including Parkinson’s disease, schizophrenia, and depression.
03Its platform is listed with the FDA as a Class II medical device.
04Founded by experts in AI and signal processing, with a team spanning science, engineering, clinical research, and business.

Technology & products3

Technology & products

Modality Multimodal Neurological and Psychiatric Assessment Platform
An AI-driven system that remotely and in-clinic assesses neurological and psychiatric conditions through speech, facial, and cognitive analysis.
Tina Virtual Agent
A conversational AI virtual guide that interacts with patients to collect speech and facial data for neurological assessments.
Patient Report of Problems™ (PROP™)
A natural language processing tool that analyzes patients’ verbatim descriptions of their symptoms and problems.

Recent updates2

Launches, partnerships and team changes from press coverage

Jul 9, 2026Partnership
Modality.AI and Amprion announced a collaboration combining multimodal digital neurology assessments with biomarker research for neurodegenerative disease.
businesswire.com
Nov 29, 2023Partnership
Verge Genomics announced that it would use Modality.AI in an ALS Phase 1b clinical trial of its lead drug candidate, VRG50635.
globenewswire.com

About Modality.AI

Products: Modality Multimodal Neurological and Psychiatric Assessment Platform, Tina Virtual Agent, Patient Report of Problems™ (PROP™)
Leadership: David Suendermann-Oeft, Founder and CEODavid Pautler, Founder and CTO
Focus areas: NeuroTechnology, digital health, medical devices, clinical research, AI/ML, neurology, mental health, multimodal analytics
Headquarters: San Francisco, CA
Founded: 2018
Employees: 11–50
Patents granted: 3 (Crunchbase)